Breaking News

Trials & Filings in Brief: Nov. 11, 2013

By Gil Roth | November 11, 2013

Acasti, Alnylam, Galena, GW, Portola, Revalasio, Zalicus

Phase I
Galena tests ovarian cancer vaccine . . . read more

GW begins GBM trial . . . read more

Phase II
Portola compound reverses Xarelto . . . read more

Revalasio begins MS trial . . . read more

Zalicus’ Z160 fails in LSR, PHN studies . . . read more

Acasti files IND for CaPre . . . read more

Alnylam gets fast track for patisiran . . . read more
  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials